Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 67.2% in November

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the target of a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 9,500 shares, a decrease of 67.2% from the October 31st total of 29,000 shares. Based on an average daily trading volume, of 22,000 shares, the short-interest ratio is presently 0.4 days. Approximately 0.2% of the company’s shares are sold short.

Analyst Ratings Changes

Several brokerages have recently weighed in on APRE. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Aprea Therapeutics in a research note on Monday, November 18th. Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of Aprea Therapeutics in a research note on Tuesday, August 13th.

Aprea Therapeutics Stock Performance

Shares of APRE stock traded up $0.01 during mid-day trading on Wednesday, hitting $2.98. 15,193 shares of the stock traded hands, compared to its average volume of 19,983. The company’s 50-day simple moving average is $3.31 and its 200-day simple moving average is $3.77. Aprea Therapeutics has a twelve month low of $2.15 and a twelve month high of $8.85. The firm has a market cap of $16.18 million, a price-to-earnings ratio of -1.06 and a beta of 0.97.

Aprea Therapeutics (NASDAQ:APRE) last announced its earnings results on Thursday, November 7th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.11. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. The business had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.45 million. Analysts forecast that Aprea Therapeutics will post -2.55 earnings per share for the current year.

Insider Activity at Aprea Therapeutics

In related news, Director Bernd R. Seizinger acquired 10,000 shares of the stock in a transaction dated Friday, October 11th. The stock was bought at an average cost of $2.68 per share, with a total value of $26,800.00. Following the purchase, the director now directly owns 44,730 shares of the company’s stock, valued at approximately $119,876.40. This represents a 28.79 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Marc Duey bought 30,000 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The shares were purchased at an average price of $4.39 per share, with a total value of $131,700.00. Following the acquisition, the director now directly owns 240,113 shares in the company, valued at approximately $1,054,096.07. This trade represents a 14.28 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 42,290 shares of company stock valued at $165,096. Company insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aprea Therapeutics stock. Dimensional Fund Advisors LP purchased a new stake in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned approximately 0.20% of Aprea Therapeutics as of its most recent SEC filing. 34.19% of the stock is owned by hedge funds and other institutional investors.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.